AUTHORS
Samira Naderinezhad, MSc, Jerald D. Noble, PhD2, Meghan A. Menges3, Aijie Liu4, Luis A. Cuadrado, MSc5, Emily C. Merritt6, Julia Llanos, BS7, Julieta Abraham Miranda8, William Sawyer9, Salvatore Corallo10, Ciara Louise L Freeman, MD, PhD11, Sean Yoder12, Constanza Savid-Frontera, PhD13, Paulo Rodriguez, PhD14, Michael D. Jain, MD, PhD15, Reginald Atkins, PhD16, Frederick L. Locke, MD17
AFFILIATIONS
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
17 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
ABSTRACT
CAR-T cell therapy is a standard treatment for several hematologic malignancies. We previously showed that Humanin-Like 8 (HN8; MTRNR2L8) expression in axicabtagene ciloleucel (axi-cel) infusion products was associated with improved clinical outcomes (Yu, JITC, 2025). Extending these observations to multiple myeloma, we reanalyzed our published single-cell RNA sequencing (scRNA-seq) dataset of idecabtagene vicleucel (ide-cel) infusion products (Noble, Blood, 2026), which identified MTRNR2L8 as one of the top differentially upregulated genes in CD4+ CAR-T cells from patients with durable responses.
HN8 is a poorly characterized peptide with high sequence similarity to the pro-survival mitochondrial encoded peptide, Humanin. CD19 CAR-T with constitutive HN8 overexpression (19.28z.HN8) improved cell survival, metabolic fitness, and cytotoxicity, while reducing exhaustion (Naderinezhad, ASH, 2025). Here, we further define HN8 function in preclinical CAR-T models and clinical CAR-T products.
In the axi-cel scRNA-seq dataset we found patients with CAR-T expressing MTRNR2L8 had greater post-infusion expansion (day 7) by flow cytometry of PBMC samples. Concordantly, 19.28z.HN8 CAR-T made from lymphoma patient’s apheresis material (n=14) had greater numbers after manufacturing compared to control 19.28z (p=0.001). Despite these favorable characteristics, 19.28z.HN8 CAR-T cells infused into mice bearing established RAJI tumors, did not demonstrate improved tumor control compared with 19.28z CAR-T (n=14 mice/group, p=0.797, hazard ratio=1.044).
Unexpectedly, we found that when equal numbers of viable CAR-T cells cryopreserved and later thawed and immediately infused into tumor-bearing immunodeficient mice, 19.28z.HN8 CAR-T treated had prolonged survival (n=13 mice/group p=0.006, hazard ratio=4.344). Because all FDA-approved CAR-T products are cryopreserved, we hypothesized HN8 acts as a cryoprotective factor. Notably, recombinant Humanin peptides have been reported to improve post-thaw sperm viability and function (Rao, Andrology, 2019).
Consistent with a cryoprotective role for HN8, MTRNR2L8-high axi-cel and ide-cel products demonstrated greater post-thaw recovery than MTRNR2L8-low products (n=9 vs. 70, p=0.045). Similarly, healthy donor-derived 19.28z.HN8 CAR-T cells exhibited improved post-thaw recovery (p=0.037) and enhanced cytotoxicity (p=0.035) following cryopreservation compared with controls.
We next demonstrated that survival was not solely attributable to greater number of viable CAR-T cells in 19.28z.HN8 after freeze-thaw, as animals treated with equal number of viable CAR-T cells after thaw also demonstrated 19.28z.HN8 CAR-T have superior survival (n=15 mice/group, p=0.037, hazard ratio=2.707). We interrogated phenotypic markers of oxidative stress and apoptosis in 19.28z.HN8 or control CAR-T after thaw, as mechanistic explanations of improved function. Indeed, 19.28z.HN8 had reduced total ROS (p=0.014), mitochondrial superoxide (p=0.016), and caspase-3/7 activation (p=0.021), despite comparable mitochondrial biomass (p=0.202).
Bulk RNA-seq was performed on paired fresh and cryopreserved/thawed 19.28z and 19.28z.HN8 CAR-T cells derived from healthy donor PBMCs (n=6). Similar to what we previously described for fresh/unfrozen, after freeze/thaw 19.28z.HN8 have decreased markers of exhaustion (ENTPD1, NT5E, TIGIT, IKZF2, CTLA4, PRDM1), and pro-apoptotic genes (TP73, TP53INP1, TP63, MT1M) with increased expression of genes associated with central memory activity (CCR7, TCF7, CD27), effector function (GZMB), pro-survival (BCL3, IER3, NPTX1, IGFBP2, NIBAN2, STAT1, STAT3, JAK3, IDH2), and cold shock response (RBM3). Interaction effects analysis showed that HN8-overexpressing CAR-T cells preferentially activated adaptive stress-response programs, including NR4A1/2/3, EGR3, and HSPA6, following cryopreservation. Cross-comparison with patient scRNA-seq data identified concordantly regulated genes in MTRNR2L8-expressing CAR-T cells, including RBM3, CD27, STAT1, TCF7, ENTPD1, TIGIT.
In summary, HN8 overexpression protects CAR-T cells from cryopreservation-associated injury and improves in vivo tumor control after CAR-T cryopreservation and thawing. These data support that HN8 overexpression reinforces adaptive stress-response pathways that maintain CAR-T cell fitness following cryopreservation.
DISCLOSURES
Samira Naderinezhad, MSc: No relevant conflicts of interest to declare.